Vyome Holdings, Inc.
NCM: HINDLive Quote
📈 ZcoreAI Score
Our AI model analyzes Vyome Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get HIND Z-Score →About Vyome Holdings, Inc.
Healthcare
Biotechnology
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
📊 Fundamental Analysis
Vyome Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -40.5% revenue growth, which is negative, indicating a recent decline in revenue.
At a current price of $2.19, HIND currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $1.75 - $56.40).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
Key Financials
Market Cap
$15.37M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
--
52W High
$56.40
52W Low
$1.75
Avg Volume
883K
Day High
Day Low